Dr. Luc Vallières is a Professor in the Department of Molecular Medicine at Laval University and a neuroimmunology researcher in the Neuroscience Unit at the CHU de Québec.
He began his career in 2002 after a postdoctoral training at the Salk Institute in California in the field of postnatal neurogenesis (1998-2001). This training was preceded by a doctorate in physiology at Laval University (1993-1998) and a bachelor’s degree in biology at the Université du Québec à Chicoutimi (1990-1993).
He is studying two diseases that afflict the central nervous system: multiple sclerosis and brain cancer. His research program aims to better understand how immune cells are regulated in these diseases in the hope of finding a way to neutralize or stimulate them for therapeutic purposes. This program is well funded by the CIHR, NSERC and Multiple Sclerosis Society of Canada.
He has made a significant contribution to the field of neuroimmunology by discovering a population of immune cells that constantly patrols the blood vessels of the nervous system and by elucidating mechanisms that govern their recruitment and functions under inflammatory conditions.
His research led to an international patent claiming the first ever drug that would specifically calm the neutrophil, an immune cell normally beneficial, but that can be involved in many inflammatory diseases.
His technical background includes single cell-RNA sequencing, STED super-resolution microscopy, flow cytometry, CRISPR-Cas9 gene editing and RNA interference, as well as bone marrow transplantation. Strong of this expertise, he directs the super-resolution microscopy and irradiation platforms at the CHU de Québec.
He is responsible of two courses, namely Principles of Neuroimmunology (MMO-7010) and Current Techniques in Molecular Medicine (MMO-7019).
Among his external activities, he is chairing the organizing committee of the 16th Congress of the International Society of Neuroimmunology, which will take place in Quebec City in August 2022. He is associate editor of the journal Mediators of Inflammation. He also serves on neuroscience committees at the CIHR.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
- Béland, Louis-CharlesEmployee+1 418-525-4444, extension 42296+1 firstname.lastname@example.org
- Morin, FrançoiseEmployeeCHUL+1 418-525-4444, extension 42296Francoise.Morin@crchudequebec.ulaval.ca
2705, boulevard Laurier
Canada G1V 4G2
- Singh, NoopurDoctoral studentCHUL+1 418-525-4444, extension email@example.com@crchudequebec.ulaval.ca
2705 Boulevard Laurier
Ville de Québec, QC
Canada G1V 4G2
- Taghipour Mirakmahaleh, RezaDoctoral firstname.lastname@example.org
- Théraulaz-Gil, CoralieEmployeecoralie.email@example.com
- Zhang, YuDoctoral firstname.lastname@example.org
NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD.Journal Article
Gut, 2021, ISSN: 0017-5749.
MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis.Journal Article
Brain, 142 (10), pp. 2979-2995, 2019, ISSN: 0006-8950.
Ultrastructural evidence of microglial heterogeneity in Alzheimer's disease amyloid pathology.Journal Article
J Neuroinflammation, 16 (1), pp. 87, 2019.
ICAM1+ neutrophils promote chronic inflammation via ASPRV1 in B cell-dependent autoimmune encephalomyelitis.Journal Article
JCI Insight, 2 (23), 2017, ISSN: 2379-3708.
Neutrophil perversion in demyelinating autoimmune diseases: Mechanisms to medicine.Journal Article
Autoimmun Rev, 16 (3), pp. 294-307, 2017, ISSN: 1568-9972.
Dark microglia: A new phenotype predominantly associated with pathological states.Journal Article
Glia, 64 (5), pp. 826-39, 2016, ISSN: 0894-1491.
Rapid externalization of 27-kDa heat shock protein (HSP27) and atypical cell death in neutrophils treated with the sphingolipid analog drug FTY720.Journal Article
J Leukoc Biol, 98 (4), pp. 591-9, 2015, ISSN: 0741-5400.
Interleukin-36γ is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis.Journal Article
J Neuroinflammation, 12 , pp. 173, 2015.
GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer's disease.Journal Article
Brain Behav Immun, 46 , pp. 112-20, 2015, ISSN: 0889-1591.
CXCL10 triggers early microglial activation in the cuprizone model.Journal Article
J Immunol, 194 (7), pp. 3400-13, 2015, ISSN: 0022-1767.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2023-05-01
- Characterization of a novel dendritic cell-specific protein in demyelinating autoimmune diseases, Subvention, Société canadienne de la sclérose en plaques, from 2019-04-01 to 2022-03-31
- Suppression of regulatory B cells by neutrophils in a model of multiple sclerosis, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-10-01 to 2023-03-31
- Suppression of regulatory B cells by neutrophils in a model of multiple sclerosis, Subvention, Société canadienne de la sclérose en plaques, from 2018-04-01 to 2021-03-31
Recently finished projects
- Évaluation du rôle de l'aspartic peptidase ASPRV1 dans l'asthme, Subvention, Fondation de l'Université Laval, from 2019-12-01 to 2020-11-30
- Mécanisme d’immunomodulation par le GPR84, un récepteur d’acides gras., Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2015-04-01 to 2020-03-31
- Production et caractérisation d'anticorps anti-ASPRV1 pour le traitement de maladies immunitaires, Partenariat, Ministère de l'Économie et de l'Innovation, Programme de soutien aux organismes de recherche et d’innovation (PSO) - Recherche-innovation - Volet 2a, from 2019-09-25 to 2020-06-30